New drug for the treatment of hypoglycemia has been registered
Mirpharm announces the successful registration of a new drug for the treatment of hypoglycemia in the form of capsules.
Moscow, January 2023
Diazoxide is a new drug in the Russian Federation that has no analogues. Production is carried out by ZAO OCPC in Obninsk, Kaluga region. Diazoxide is a derivative of benzothiadiazine but has no diuretic effect. When taken orally, Diazoxide causes a rapid dose-dependent increase in a blood glucose level (both by inhibiting the release of insulin (the hormone that lowers the blood sugar level) from the pancreas, and through direct extrapancreatic action). Hyperglycemic effect comes into effect within the first hour after oral ingestion and usually lasts no longer than 8 hours subject to patients having normal renal function. Diazoxide reduces sodium ion excretion, resulting in fluid retention, which may be clinically significant. It refers to a group of drugs for the treatment of hypoglycemia (low blood sugar).
Indications for use:
The drug Diazoxide is indicated for the elimination of hypoglycemia in patients with hyperinsulinemia that has developed:
- in adults with inoperable extrapancreatic tumor or pancreatic cell tumor (both malignant and benign) that carries out insulin synthesis;
- in children aged 0 to 18 years with:
● leucine-sensitive pancreatic cell hyperplasia (a disease in which an amino acid called leucine stimulates insulin production due to an inherited defect);
● nesidioblastosis (neonatal hypoglycemic syndrome due to total transformation of the ductal epithelium of pancreatic islet cells), extrapancreatic localization of insulin-producing cells, pancreatic islet cell tumor.
Diazoxide can be used preoperatively as a temporary measure and postoperatively if hypoglycemia persists. If there is no improvement or a situation worsens, you should consult a doctor.
Available dosages: 25 and 100 mg.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising, (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.